These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9329355)

  • 1. Growth hormone (GH) replacement reduces total body fat and normalizes insulin sensitivity in GH-deficient adults: a report of one-year clinical experience.
    Hwu CM; Kwok CF; Lai TY; Shih KC; Lee TS; Hsiao LC; Lee SH; Fang VS; Ho LT
    J Clin Endocrinol Metab; 1997 Oct; 82(10):3285-92. PubMed ID: 9329355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuation of growth hormone (GH) therapy in GH-deficient patients during transition from childhood to adulthood: impact on insulin sensitivity and substrate metabolism.
    Nørrelund H; Vahl N; Juul A; Møller N; Alberti KG; Skakkebaek NE; Christiansen JS; Jørgensen JO
    J Clin Endocrinol Metab; 2000 May; 85(5):1912-7. PubMed ID: 10843174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of growth hormone (GH) on glycerol and free fatty acid metabolism during exhaustive exercise in GH-deficient adults.
    Gibney J; Healy ML; Stolinski M; Bowes SB; Pentecost C; Breen L; McMillan C; Russell-Jones DL; Sonksen PH; Umpleby AM
    J Clin Endocrinol Metab; 2003 Apr; 88(4):1792-7. PubMed ID: 12679475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuation of growth hormone therapy versus placebo in transition-phase patients with growth hormone deficiency: impact on body composition, insulin sensitivity, and thyroid function.
    Jørgensen JO; Nørrelund H; Vahl N; Juul A; Skakkebaek NE; Christiansen JS
    J Pediatr Endocrinol Metab; 2002 Dec; 15 Suppl 5():1355-60. PubMed ID: 12510991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults.
    Weaver JU; Monson JP; Noonan K; John WG; Edwards A; Evans KA; Cunningham J
    J Clin Endocrinol Metab; 1995 Jan; 80(1):153-9. PubMed ID: 7829604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults.
    Svensson J; Fowelin J; Landin K; Bengtsson BA; Johansson JO
    J Clin Endocrinol Metab; 2002 May; 87(5):2121-7. PubMed ID: 11994351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth hormone treatment of adults with Prader-Willi syndrome and growth hormone deficiency improves lean body mass, fractional body fat, and serum triiodothyronine without glucose impairment: results from the United States multicenter trial.
    Mogul HR; Lee PD; Whitman BY; Zipf WB; Frey M; Myers S; Cahan M; Pinyerd B; Southren AL
    J Clin Endocrinol Metab; 2008 Apr; 93(4):1238-45. PubMed ID: 18211968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of the deterioration of insulin sensitivity on beta-cell function in growth-hormone-deficient adults following 4-month growth hormone replacement therapy.
    Rosenfalck AM; Fisker S; Hilsted J; Dinesen B; Vølund A; Jørgensen JO; Christiansen JS; Madsbad S
    Growth Horm IGF Res; 1999 Apr; 9(2):96-105. PubMed ID: 10373342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in subcutaneous and visceral fat mass during growth hormone replacement therapy in adult men.
    de Boer H; Blok GJ; Voerman B; Derriks P; van der Veen E
    Int J Obes Relat Metab Disord; 1996 Jun; 20(6):580-7. PubMed ID: 8782736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discontinuing long-term GH replacement therapy--a randomized, placebo-controlled crossover trial in adult GH deficiency.
    Filipsson Nyström H; Barbosa EJ; Nilsson AG; Norrman LL; Ragnarsson O; Johannsson G
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3185-95. PubMed ID: 22791760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation.
    Lo JC; Mulligan K; Noor MA; Schwarz JM; Halvorsen RA; Grunfeld C; Schambelan M
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3480-7. PubMed ID: 11502767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.
    Fernholm R; Bramnert M; Hägg E; Hilding A; Baylink DJ; Mohan S; Thorén M
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4104-12. PubMed ID: 11095440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circadian and ultradian rhythm and leptin pulsatility in adult GH deficiency: effects of GH replacement.
    Ahmad AM; Guzder R; Wallace AM; Thomas J; Fraser WD; Vora JP
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3499-506. PubMed ID: 11502770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients.
    Nam SY; Kim KR; Cha BS; Song YD; Lim SK; Lee HC; Huh KB
    Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1101-7. PubMed ID: 11477493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defects of insulin action and skeletal muscle glucose metabolism in growth hormone-deficient adults persist after 24 months of recombinant human growth hormone therapy.
    Christopher M; Hew FL; Oakley M; Rantzau C; Alford F
    J Clin Endocrinol Metab; 1998 May; 83(5):1668-81. PubMed ID: 9589675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency.
    Yuen KC; Frystyk J; White DK; Twickler TB; Koppeschaar HP; Harris PE; Fryklund L; Murgatroyd PR; Dunger DB
    Clin Endocrinol (Oxf); 2005 Oct; 63(4):428-36. PubMed ID: 16181235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of GH replacement in adult GH-deficient patients: changes in body composition without concomitant changes in the adipokines and insulin resistance.
    Hana V; Silha JV; Justova V; Lacinova Z; Stepan JJ; Murphy LJ
    Clin Endocrinol (Oxf); 2004 Apr; 60(4):442-50. PubMed ID: 15049958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of 30 months of low-dose replacement therapy with recombinant human growth hormone (rhGH) on insulin and C-peptide kinetics, insulin secretion, insulin sensitivity, glucose effectiveness, and body composition in GH-deficient adults.
    Rosenfalck AM; Maghsoudi S; Fisker S; Jørgensen JO; Christiansen JS; Hilsted J; Vølund AA; Madsbad S
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4173-81. PubMed ID: 11095450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of continuation or cessation of growth hormone (GH) therapy on body composition and metabolic status in adolescents with severe GH deficiency at completion of linear growth.
    Carroll PV; Drake WM; Maher KT; Metcalfe K; Shaw NJ; Dunger DB; Cheetham TD; Camacho-Hübner C; Savage MO; Monson JP
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3890-5. PubMed ID: 15292323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth hormone binding protein correlates strongly with leptin and percentage body fat in GH-deficient adults, is increased by GH replacement but does not predict IGF-I response.
    Florkowski CM; Barnard R; Livesey JH; Veveris T; Espiner EA; Donald RA
    Growth Horm IGF Res; 1999 Feb; 9(1):35-40. PubMed ID: 10207506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.